IPS HEART
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • Home
  • About Us
  • Our Approach
  • Our Pipeline
  • Why Heart Disease?
  • Why DMD?
  • Platform
  • Publications
  • Clinical Efficacy
  • More
    • Home
    • About Us
    • Our Approach
    • Our Pipeline
    • Why Heart Disease?
    • Why DMD?
    • Platform
    • Publications
    • Clinical Efficacy
IPS HEART

Signed in as:

filler@godaddy.com

  • Home
  • About Us
  • Our Approach
  • Our Pipeline
  • Why Heart Disease?
  • Why DMD?
  • Platform
  • Publications
  • Clinical Efficacy

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Next generation stem cell Clinical Efficacy

IPS/Pluripotent Stem Cell hUMAN dATA HAS ARRived

The New York Times

The New York Times

The New York Times

Reports of restored functional benefit in diabetic patients by creating new insulin producing beta cells.

The Lancet

The New York Times

The New York Times

Restored eyesight in over half of patients by creating new retinal pigment epithelium.

JACC Journals

The Wall Street Journal

The Wall Street Journal

Restored heart function as pluripotent derived cardiac progenitor cells (CPCs) by IPS HEART Advisor Dr. Menasche in his Phase I clinical trial in Paris increased left ventricular ejection fraction (LVEF) from 26% to 38% after three months with no safety issues.

The Wall Street Journal

The Wall Street Journal

The Wall Street Journal

Scientists are reverse-engineering patients’ own skin or blood cells to behave similarly to embryonic cells and using them in tests to treat incurable diseases.

Copyright © 2014 IPS HEART - All Rights Reserved.